NZ596419A - Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders - Google Patents

Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders

Info

Publication number
NZ596419A
NZ596419A NZ596419A NZ59641910A NZ596419A NZ 596419 A NZ596419 A NZ 596419A NZ 596419 A NZ596419 A NZ 596419A NZ 59641910 A NZ59641910 A NZ 59641910A NZ 596419 A NZ596419 A NZ 596419A
Authority
NZ
New Zealand
Prior art keywords
disorders
fibrosis
treatment
ocular
scarring
Prior art date
Application number
NZ596419A
Other languages
English (en)
Inventor
Ian Alexander Mcdonald
Diego Silva
Alan D Robertson
Original Assignee
Pharmaxis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaxis Ltd filed Critical Pharmaxis Ltd
Publication of NZ596419A publication Critical patent/NZ596419A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ596419A 2009-04-28 2010-04-28 Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders NZ596419A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17341609P 2009-04-28 2009-04-28
PCT/IB2010/000960 WO2010125445A1 (en) 2009-04-28 2010-04-28 Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders

Publications (1)

Publication Number Publication Date
NZ596419A true NZ596419A (en) 2014-01-31

Family

ID=43031758

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ596419A NZ596419A (en) 2009-04-28 2010-04-28 Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders

Country Status (10)

Country Link
US (1) US8557783B2 (cg-RX-API-DMAC7.html)
EP (1) EP2424542A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012525369A (cg-RX-API-DMAC7.html)
KR (1) KR20120049183A (cg-RX-API-DMAC7.html)
AU (1) AU2010243314C1 (cg-RX-API-DMAC7.html)
CA (1) CA2760253A1 (cg-RX-API-DMAC7.html)
IL (1) IL215990A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ596419A (cg-RX-API-DMAC7.html)
SG (1) SG175816A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010125445A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2926480A1 (en) * 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
JP7466927B2 (ja) * 2018-08-10 2024-04-15 ニューヨーク ユニバーシティ アンジェルマン症候群及び自閉症を治療するためのｉｇｆ―２受容体作動剤リガンドの使用
WO2020033972A1 (en) 2018-08-10 2020-02-13 New York University Use of mannose 6 phosphate and modifications thereof for memory enhancement and reducing memory impairment
CN113301925A (zh) 2018-12-19 2021-08-24 小利兰·斯坦福大学理事会 用于溶酶体靶向的双官能分子以及相关的组合物和方法
CN113368106B (zh) * 2020-02-25 2023-09-29 渐宽(苏州)生物科技有限公司 艾托莫德用于防治特发性肺纤维化的药物中的用途
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
CA3226269A1 (en) 2021-07-14 2023-01-19 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ872300A0 (en) * 2000-07-11 2000-08-03 Praxis Pharmaceuticals Pty Ltd Compounds and methods
DE602004022659D1 (de) * 2003-05-20 2009-10-01 Pharmaxis Pty Ltd Mannose-6-phosphonat-verbindungen zur behandlung von entzündungskrankheiten
FR2930942B1 (fr) 2008-05-07 2011-03-04 Centre Nat Rech Scient Nouvelles utilisations de derives de d-mannopyranose activateurs de l'angiogenese
FR2930943B1 (fr) 2008-05-07 2011-03-18 Centre Nat Rech Scient Nouvelles utilisations de derives de d-mannopyranose inhibiteurs de l'angiogenese

Also Published As

Publication number Publication date
EP2424542A4 (en) 2012-12-19
IL215990A0 (en) 2012-01-31
EP2424542A1 (en) 2012-03-07
JP2012525369A (ja) 2012-10-22
US20120045455A1 (en) 2012-02-23
WO2010125445A1 (en) 2010-11-04
AU2010243314A1 (en) 2011-12-01
KR20120049183A (ko) 2012-05-16
AU2010243314B2 (en) 2015-07-02
SG175816A1 (en) 2011-12-29
AU2010243314C1 (en) 2015-11-12
CA2760253A1 (en) 2010-11-04
US8557783B2 (en) 2013-10-15

Similar Documents

Publication Publication Date Title
NZ596419A (en) Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders
WO2013126781A3 (en) Expandable endoscopic hoods
EP2670486A1 (en) Treatment for lipodystrophy
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
MX365986B (es) Derivativos de piperidina fusionados con espiro para usarse como inhibidores del canal de potasio medular externo renal.
EA201591774A1 (ru) Замещенные ароматические соединения для лечения легочного фиброза, фиброза печени, фиброза кожи и фиброза сердца
WO2010088050A3 (en) Bicyclic pyrazolo-heterocycles
WO2009120660A3 (en) Substituted pyridoxazines
MX338431B (es) Fijador de tejido.
WO2008157751A3 (en) Substituted imidazoheterocycles
GB201109620D0 (en) Injection apparatus
RU2012107109A (ru) Бициклическое соединение и его применение для медицинских целей
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof
PH12012501358A1 (en) Treatment method
WO2011026911A8 (en) Bipyridines useful for the treatment of proliferative diseases
RU2013129484A (ru) Алкиновые и алкеновые производные в качестве модуляторов рецептора сфингозин 1-фосфата-1
WO2011113507A3 (en) Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns
NZ597866A (en) Therapeutic lactams
EA201390292A1 (ru) Ингибиторы деацетилазы на основе гидроксамата
RU2013129483A (ru) Новые фениловые производные оксадиазола в качестве модуляторов рецептора сфингозин 1-фосфата (s1p)
WO2012074869A8 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
NZ598490A (en) Treatment of macular degeneration
WO2020236690A9 (en) Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
EA201101210A1 (ru) 5-(2-{[6-(2,2-дифтор-2-фенилэтокси)гексил]амино}-1-гидроксиэтил)-8-гидроксихинолин-2(1h)-oh для лечения легочной функции
NZ702835A (en) 3-o-heteroaryl-ingenol

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 APR 2017 BY DAVIES COLLISON CAVE

Effective date: 20140502

LAPS Patent lapsed